Long Covid: Almost one in 10 may have condition, research finds
Almost one in 10 people in England think they could have long Covid, according to analysis of national data.University of Southampton researchers examined information collected by NHS England that showed 4.8% of people reported having the condition.The analysis of more than 750,000 responses to the GP Patient Survey also found that 9.1% of people believe they may have long Covid.Long Covid is a chronic condition induced by Covid-19 infection, with symptoms including fatigue, feeling short of breath, brain fog, and heart palpitations.
The information also shows higher rates of long Covid in deprived areas and people with particular ethnic backgrounds, parents, carers and those with another long-term condition.Professor Nisreen Alwan, who co-authored the study, said the analysis "adds further evidence of the unfairness of long Covid", with people who are "already disadvantaged in society more likely to be affected"."It also shows us that many people aren't sure if they have it, and may need diagnosis, treatment and support."He said the condition was "still a very significant issue impacting individuals, families, the economy and wider society"."We need to do more to prevent it, diagnose it, and properly support people who are affected by it," he added.Researchers found that people aged under 25, males, from particular ethnic minorities, or those without long-term conditions were more likely to be unsure if they had long Covid.They also found men who thought they may have the condition were generally less likely to seek medical advice than women.Mirembe Woodrow, who is studying for a PhD at Southampton, carried out the analysis: "We were really surprised to find so many people weren't sure whether they had long Covid or not, and the study shows there is still work to do to increase awareness of the condition and remove barriers to accessing diagnosis, treatment and support.""We don't want long Covid to be another factor that contributes to the widening health gap in the UK."
You can follow BBC Hampshire & Isle of Wight on Facebook, X, or Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
2 hours ago
- NBC News
Covid vaccination protects against severe kidney damage, study suggests
Complications from a Covid infection can harm the heart, brain, lungs and kidneys. A new study finds that patients hospitalized for Covid were less likely to suffer severe kidney damage if they were vaccinated. Researchers at UCLA Health analyzed electronic medical records at a large academic hospital between March 1, 2020, and March 30, 2022, of approximately 3,500 hospitalized patients, ages 18 and older, and compared hospitalized patients who got at least two primary doses of the Moderna or Pfizer mRNA vaccine or one dose of Johnson & Johnson Janssen vaccine for Covid with hospitalized patients who had not been vaccinated. The researchers examined which participants developed kidney disease severe enough to require a type of dialysis known as CRRT, or continuous renal replacement therapy. The nonstop dialysis therapy does the work of the kidneys by filtering and removing waste from the blood. It's typically used when a patient is in intensive care, said lead author Dr. Niloofar Nobakht, health sciences clinical associate professor of medicine in nephrology at UCLA Health. The study found that 16% of unvaccinated patients with Covid were more likely to need CRRT, compared with 11% of vaccinated patients during their hospital admission. Unvaccinated patients were more than two-and-a-half times as likely to need CRRT after leaving the hospital — and also had a much higher risk of dying after being discharged, compared with vaccinated patients. In a 2021 study, researchers at Yale University School of Medicine found that among hospitalized patients with Covid, approximately 30% develop acute kidney injury — an abrupt, usually reversible form of kidney dysfunction. Patients hospitalized with Covid were twice as likely to need dialysis than patients hospitalized for other reasons. There is a major limitation in the new study. The researchers did not have the full data on baseline kidney status for the patients —meaning, it's not known how well their kidneys were functioning before the infection — so the benefits of the vaccine may be overestimated or underestimated, said Dr. Scott Roberts, associate medical director of infection prevention at Yale School of Medicine, who was not part of the new study. How Covid can damage the kidneys Covid can injure the kidneys either directly or by damaging other organs such as the heart and lungs, Roberts said. The more severe the symptoms, the greater the risk. 'Conversely, mild or asymptomatic infections rarely cause significant kidney harm,' said Yong Chen, a professor of biostatistics and director of the Center for Health AI and Synthesis of Evidence at the University of Pennsylvania, who was not associated with the new study. Chen researches Covid complications, including kidney problems, in children and adolescents. The risk of post-Covid kidney complications is especially high in older people or the immunocompromised, but it's likely connected to the severity of the initial infection, rather than the virus itself, experts say. 'Comparing Covid to people hospitalized with flu, for example, shows that both have an elevated risk of kidney injury, and it seems to track with how sick they were during their hospitalization,' said Dr. F. Perry Wilson, associate professor of medicine and public health at Yale University School of Medicine who has studied kidney injury in Covid patients. 'Among people with Covid, I would expect that, all else being equal, the vaccinated group just has less severe disease and thus less kidney trouble.' Why vaccination may protect the kidneys 'Vaccination protects kidneys mainly by preventing the severe forms of Covid that cause kidney injury,' Chen said. 'While vaccines don't directly shield kidney cells, they blunt the systemic illness that otherwise leads to multi-organ failure.' However, both Covid infection and the vaccines may be risky for people with glomerulonephritis, a type of kidney disease where the filtering units known as glomeruli get damaged Dr. Jeffrey S. Berns, clinical nephrologist and professor of medicine and pediatrics at the Hospital of the University of Pennsylvania, said there are reports of adults and children with glomerulonephritis having a relapse of the condition or developing the condition for the first time following Covid infection and also vaccination. Berns was not part of the study. Risks for children The study only applied to people 18 and older, but experts say children with Covid can get acute kidney injury and some of them may have permanent kidney damage. 'In a study led by our team, the results also showed that children with prior Covid had a 35% higher risk of new-onset chronic kidney disease over six months,' Chen said. In late May, Health and Human Services Secretary Robert F. Kennedy Jr. said the Centers for Disease Control and Prevention will no longer recommend routine Covid shots for healthy children and pregnant women. Doctors say it's too soon to know whether the revised guidelines would contribute to unvaccinated children's increased risk of kidney injury. Even as a new variant of the Covid virus is gaining momentum in the United States, there are fewer cases of acute kidney injury associated with the illness than in the early years of the pandemic. 'As more and more people got vaccinated and or had some degree of immunity from prior infection, disease severity was not as bad and AKI became much less common,' Berns said.
ITV News
3 hours ago
- ITV News
World-first 'Trojan horse' drug to be given to blood cancer patients in England
Blood cancer patients in England will be among the first in the world to have access to a new 'Trojan horse' treatment, health officials have announced. Studies suggest the targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments. It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment. It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use. NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can now be offered to patients whose cancer has progressed or has not responded to another first-line treatment. The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future.'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation.'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
Wales Online
4 hours ago
- Wales Online
Nimbus Covid variant has one very specific painful symptom, doctors say
Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info Doctors have highlighted a distinct symptom of the rapidly emerging new Covid strain known as Nimbus, which has been increasingly detected in the UK since January. While vaccines and prior infections are deemed approximately half as effective at thwarting Nimbus compared to other variants, a particular symptom sets it apart. Cases globally are ascending as this variant takes hold, with the UK witnessing its presence. A representative from the World Health Organisation remarked: "Currently approved COVID-19 vaccines are expected to remain effective against this variant against symptomatic and severe disease. Despite a concurrent increase in cases and hospitalizations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation." The hallmark symptom termed 'razor blade throat' has afflicted patients with a sharply sore throat, leaving some battling a raspy voice. Mohamed Imran Lakhi, Director and Superintendent Pharmacist at Prescription Doctor, told the Mirror: "People commonly report a severe sore throat, persistent fatigue, mild cough, fever, muscle aches, and nasal congestion. Some also experience digestive issues like nausea or diarrhoea, which isn't always typical with Covid variants.", reports Wales Online. Dr Naveed Asif, a GP at The London General Practice, notes that the NB. 1.8. 1 variant is characterised by a severe sore throat, often described as a "razor blade sensation". This is typically a sharp, stabbing pain experienced when swallowing, usually at the back of the throat. Medical experts reassure this new variant poses no greater threat than previous mutations. Preventative measures remain the same, focusing on good hygiene practices such as hand washing, wearing masks in crowded areas, and avoiding individuals who are unwell. Treatment for the variant follows established protocols, including rest, hydration, and pain management with over-the-counter medication. If symptoms persist, worsen, or cause concern for yourself or another, consulting a GP or contacting 111 is advised. In cases of severe distress, such as difficulty breathing, it is crucial to call 999 immediately. Sign up for the North Wales Live newsletter sent twice daily to your inbox Find out what's happening near you
